Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BuMel Conditioning and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma
NCT01702831Phase 2Completed
- Sponsor
- University Health Network
- Start
- Oct 2013
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, melphalan, lenalidomide in multiple myeloma (MM), sponsored by University Health Network. Started Oct 2013; status: completed.
02
Drugs
busulfanmelphalanlenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01702831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01702831.